Steven Ramael
Gosselies, WAL, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Clinical Pharmacokinetics, Mass Balance and Metabolism of Fezolinetant in Postmenopausal Women.
Journal: European journal of drug metabolism and pharmacokinetics
Published: October 31, 2025
Concentration-QTc Modeling to Support Clinical Development of Fezolinetant.
Journal: Clinical pharmacology in drug development
Published: June 23, 2025
Randomized phase 2a trial assessing a novel septin molecular glue in Alzheimer's disease.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: April 08, 2025
SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement.
Journal: Frontiers in pharmacology
Published: October 11, 2022
Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.
Journal: The Journal of clinical endocrinology and metabolism
Published: September 22, 2020
Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
Journal: Menopause (New York, N.Y.)
Published: August 10, 2020
A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
Journal: Menopause (New York, N.Y.)
Published: February 27, 2020
Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
Journal: The Journal of clinical endocrinology and metabolism
Published: March 20, 2019
Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men.
Journal: Clinical drug investigation
Published: April 30, 2018
Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies.
Journal: Clinical and translational science
Published: December 05, 2017
First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: September 07, 2016
Last Updated: 09/26/2026